Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA – Nasdaq
Wolcott Daily |
Abeona Therapeutics Reports Top-Line Data from Phase 1/2 Gene Therapy Trial in MPS IIIA
Nasdaq NEW YORK and CLEVELAND, Feb. 08, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today … Abeona's Sanfilippo Gene Therapy Data Produces Encouraging Results Abeona's gene therapy candidate for Sanfilippo B shows encouraging effect in first patient; shares up 12% Why Abeona Therapeutics Jumped 14% on Wednesday |
